Comparing Para-clinical and Laboratory Methods of Covid-19 Diagnosis in Iran
Archives of Advances in Biosciences,
Vol. 13 No. 2 (2022),
1 January 2022
,
Page 1-10
https://doi.org/10.22037/aab.v13i.37244
Abstract
Introduction: Coronavirus Disease (COVID-19) caused by Severe Acute Respiratory
Syndrome Coronavirus (SARS-CoV-2) was first discovered in China in late 2019 and spread
rapidly worldwide. This study aimed to correlate positive real time Reverse Transcriptase
Polymerase Reaction (RT-PCR) results after one month of follow-up with laboratory findings
of the same patients at hospital admission to predict clinical outcome and diagnosis.
Materials and Methods: We conducted a retrospective study on the laboratory findings of
299 adult patients suspected of COVID-19. Patients were admitted to hospital from March
21 to May 25, 2021 with final follow-up of one month for each patient. After one month of
follow-up, 233 patients recovered; however, in 64 patients the symptoms worsened. For these
patients RT-PCR was performed and some patients needed chest Computed Tomography
(CT) imaging and were hospitalized. We extracted laboratory findings of these 64 patients and
correlated the results of their RT-PCR with their laboratory findings.
Results: Based on our findings, severe cases are middle-aged adults (P=0.001) with
lymphopenia (P<0.001), decreased levels of white blood cells (WBCs) (P<0.001), and platelets
(P=0.007) count along with elevated COVID-19 IgG antibody (P=0.002) and Erythrocyte
Sedimentation Rate (ESR) (P<0.001).
Conclusion: RT-PCR is not necessary at admission; instead, some routine hematology
examinations and serological tests can predict the prognosis of COVID- 19 disease.
- SARS-CoV-2; COVID-19; laboratory findings; clinical outcome
How to Cite
References
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-3. [DOI:10.1038/s41586-020-2012-7] [PMID] [PMCID]
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265-9. [DOI:10.1038/s41586-020-2008-3] [PMID] [PMCID]
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-3. [DOI:10.1016/S0140-6736(20)30185-9]
Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020; 92(4):418-23. [DOI:10.1002/jmv.25681] [PMID] [PMCID]
Fung TS, Liu DX. Human coronavirus: Host-pathogen interaction. Annu Rev Microbiol. 2019; 73:529-57. [DOI:10.1146/annurev-micro-020518-115759] [PMID]
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 181(2):281-92. e6. [DOI:10.1016/j.cell.2020.02.058] [PMID] [PMCID]
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2):271-80.e8. [DOI:10.1016/j.cell.2020.02.052] [PMID] [PMCID]
Shang J, Wan Y, Liu C, Yount B, Gully K, Yang Y, et al. Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry. PLoS Pathog. 2020; 16(3):e1008392. [DOI:10.1371/journal.ppat.1008392] [PMID] [PMCID]
Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020; 5(4):562-9. [DOI:10.1038/s41564-020-0688-y] [PMID] [PMCID]
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020; 38(1):1-9. [PMID]
Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020; 323(16):1610-2. [DOI:10.1001/jama.2020.3227] [PMID] [PMCID]
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. [DOI:10.1016/S0140-6736(20)30183-5]
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18):1708-20. [DOI:10.1056/NEJMoa2002032] [PMID] [PMCID]
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-9. [DOI:10.1001/jama.2020.1585] [PMID] [PMCID]
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 395(10229):1054-62. [DOI:10.1016/S0140-6736(20)30566-3]
Nakeshbandi M, Maini R, Daniel P, Rosengarten S, Parmar P, Wilson C, et al. The impact of obesity on COVID-19 complications: A retrospective cohort study. Int J Obes (Lond). 2020; 44(9):1832-7. [DOI:10.1038/s41366-020-0648-x] [PMID] [PMCID]
Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020; 7(1):4. [DOI:10.1186/s40779-020-0233-6] [PMID] [PMCID]
Younes N, Al-Sadeq DW, Al-Jighefee H, Younes S, Al-Jamal O, Daas HI, et al. Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2. Viruses. 2020; 12(6):582. [DOI:10.3390/v12060582] [PMID] [PMCID]
World Health Organization. Laboratory testing for coronavirus disease ( COVID-19) in suspected human cases: Interim guidance, 19 March 2020. Geneva: World Health Organization; 2020. https://apps.who.int/iris/handle/10665/331501
Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020; 323(22):2249-51. [DOI:10.1001/jama.2020.8259] [PMID]
vom Steeg LG, Klein SL. SeXX matters in infectious disease pathogenesis. PLoS Pathog. 2016; 12(2):e1005374. [DOI:10.1371/journal.ppat.1005374] [PMID] [PMCID]
Racine R, Winslow GM. IgM in microbial infections: Taken for granted? Immunol Lett. 2009; 125(2):79-85. [DOI:10.1016/j.imlet.2009.06.003] [PMID] [PMCID]
Farghaly S, Makboul M. Correlation between age, sex, and severity of Coronavirus disease-19 based on chest computed tomography severity scoring system. Egypt J Radiol Nucl Med. 2021; 52(1):23. [DOI:10.1186/s43055-021-00408-1] [PMCID]
Frater JL, Zini G, d’Onofrio G, Rogers HJ. COVID‐19 and the clinical hematology laboratory. Int J Lab Hematol. 2020; 42(Suppl 1):11-8. [DOI:10.1111/ijlh.13229] [PMID] [PMCID]
Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020; 506:145-8. [DOI:10.1016/j.cca.2020.03.022] [PMID] [PMCID]
Asghar M, Hussain N, Shoaib H, Kim M, Lynch TJ. Hematological characteristics of patients in coronavirus 19 infection: A systematic review and meta-analysis. J Community Hosp Intern Med Perspect. 2020; 10(6):508-13. [PMID] [PMCID]
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-81. [DOI:10.1016/S2213-2600(20)30079-5]
Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Signal Transduct Target Ther. 2020; 5(1):33. [DOI:10.1038/s41392-020-0159-1] [PMID] [PMCID]
Zhou L, Liu HG. [Early detection and disease assessment of patients with novel coronavirus pneumonia (Chinese)]. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43(0):E003. [PMID]
- Abstract Viewed: 549 times
- PDF Downloaded: 40 times
- MP3 Downloaded: 11 times